Commercializing Therapies for Rare and Critical Care Populations

Session details:

Rare and critical care markets differ fundamentally from traditional pharma, defined by small, fragmented patient populations, time-critical decisions, high stakes clinical settings, and variable demand where supply reliability is critical. In this presentation, Vanessa Wolfeler, CEO of SERB Pharmaceuticals, will draw on the company's extensive experience delivering medicines for rare and urgent conditions to share real-world case studies of successful commercialization in these complex environments.